Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or XXXX : results from the European exenatide study.

@entity1 @entity6 @entity16024 @entity3916 @entity1674 @entity5736 @entity164 @entity65 @entity413 @entity165 @entity2449
OBJECTIVE: The risk of @entity65 and mortality is significantly increased in @entity1 with @entity6 ; thus, it is important to determine whether @entity413 -lowering therapy affects this risk over time. Changes in cardiovascular risk markers were examined in @entity1 with @entity164 2 @entity6 treated with exenatide twice daily (a glucagon-like peptide-1 receptor agonist) or @entity16024 (a @entity5736 ) added to @entity2449 in the EURopean EXenAtide (EUREXA) study. RESEARCH DESIGN AND METHODS: @entity1 with @entity164 2 @entity6 failing @entity2449 were randomized to add-on exenatide twice daily (n  =  515) or @entity16024 (n  =  514) until treatment failure defined by hemoglobin @entity3916 . Anthropomorphic measures, blood pressure (BP), heart rate, lipids, and high-sensitivity C-reactive protein (hsCRP) over time were evaluated. RESULTS: Over 36  months, twice-daily exenatide was associated with improved body weight (-3.9  kg), waist circumference (-3.6  cm), systolic/diastolic BP (-2.5/-2.6  mmHg), high-density lipoprotein (HDL)- @entity165 (0.05  mmol/L), @entity1674 (-0.2  mmol/L), and hsCRP (-1.7  mg/L). Heart rate did not increase (-0.3 beats/minute), and low-density lipoprotein- @entity165 (0.2  mmol/L) and total @entity165 (0.1  mmol/L) increased slightly. Between-group differences were significantly in favor of exenatide for body weight (P  <  0.0001), waist circumference (P  <  0.001), systolic BP (P  <  0.001), diastolic BP (P  =  0.023), HDL- @entity165 (P  =  0.001), and hsCRP (P  =  0.004). Fewer @entity1 randomized to exenatide twice daily versus @entity16024 required the addition of at least one antihypertensive (20.4 vs 26.4  %; P  =  0.026) or lipid-lowering medication (8.4 vs 12.8  %; P  =  0.025). CONCLUSIONS: Add-on exenatide twice daily was associated with significant, sustained improvement in several cardiovascular risk markers in @entity1 with @entity164 2 @entity6 versus @entity16024 . CLINICAL TRIAL REGISTRATION: NCT00359762, http://www.ClinicalTrials.gov.
